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Vaccinia-related kinase 1 (VRK1) and VRK3 are members of 
the VRK family of serine/threonine kinases and are principally 
localized in the nucleus. Despite the crucial roles of VRK1/ 
VRK3 in physiology and disease, the molecular and functional 
interactions of VRK1/VRK3 are poorly understood. Here, we 
identified over 200 unreported VRK1/VRK3-interacting can-
didate proteins by affinity purification and LC-MS/MS. The 
networks of VRK1 and VRK3 interactomes were found to be 
associated with important biological processes such as the cell 
cycle, DNA repair, chromatin assembly, and RNA processing. 
Interactions of interacting proteins with VRK1/VRK3 were 
confirmed by biochemical assays. We also found that phos-
phorylations of XRCC5 were regulated by both VRK1/VRK3, 
and that of CCNB1 was regulated by VRK3. In liver cancer 
cells and tissues, VRK1/VRK3 were highly upregulated and its 
depletion affected cell cycle progression in the different phas-
es. VRK3 seemed to affect S phase progression and G2 or M 
phase entry and exit, whereas VRK1 affects G1/S transition in 
the liver cancer, which could be explained by different inter-
acting candidate proteins. Thus, this study not only provides a 
resource for investigating the unidentified functions of VRK1/ 
VRK3, but also an insight into the regulatory roles of 
VRK1/VRK3 in biological processes. 
 
Keywords: ESI-MS/MS, interactome, VRK1, VRK3 
 
 
INTRODUCTION 
 
Vaccinia-related kinases (VRKs) are a family of serine/threonine 
kinases, composed of VRK1–3 in mammals (Klerkx et al., 
2009). They share a similar serine/threonine protein kinase 
domain (Klerkx et al., 2009). VRK1 and VRK3 have a nuclear 
localization signal on the C- and N-terminals, respectively, 
whereas VRK2 contains a transmembrane domain on the C-
terminal (Lopez-Borges and Lazo, 2000). Among three VRK 
family proteins, VRK1 is the most extensively studied protein. 
Some of proteins that interact with VRK1 are characterized 
(Valbuena et al., 2011), and reports suggest that VRK1 plays 
a crucial role in cancer progression by targeting several sub-
strates involved in the cell cycle or DNA repair (Lee et al., 
2015b; Monsalve et al., 2016; Valbuena et al., 2011). p53 
has been identified as a substrate protein regulated by VRK1 
(Lopez-Borges and Lazo, 2000). VRK1 specifically phos-
phorylates p53 at Thr18, leading to the stabilization and 
subsequent accumulation of p53 (Lopez-Borges and Lazo, 
2000; Lopez-Sanchez et al., 2014; Vega et al., 2004). VRK1 
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phosphorylates barrier-to-autointegration factor (BAF), which 
induces the disassembly of a complex containing chromatin, 
LEM proteins, and BAF (Gorjanacz et al., 2007; Nichols et al., 
2006). Furthermore, VRK1 binds and phosphorylates several 
transcription factors such as ATF2 (Sevilla et al., 2004b), 
CREB1 (Kang et al., 2008), and c-Jun (Sevilla et al., 2004a) 
and histone proteins such as mitotic histone H3 (Kang et al., 
2007), macroH2A1 (Kim et al., 2012), and H2AX (Salzano et 
al., 2015). In addition, HnRNP A1 is phosphorylated by VRK1 
to stimulate telomerase (Choi et al., 2012). NBS1 also inter-
acts with and is phosphorylated by VRK1 at Ser343, which 
stabilizes NBS1 protein in response to DNA damage 
(Monsalve et al., 2016). 
Compared with VRK1, VRK3-interacting proteins have 
been less identified. VRK3 interacts with the phosphatase 
VHR and inhibits its phosphatase activity in a kinase-
independent manner (Kang and Kim, 2006). Indeed, VRK3 
was initially reported to be a pseudokinase (Nichols and 
Traktman, 2004). However, we confirmed the kinase activity 
of VRK3 by demonstrating the VRK3-mediated phosphoryla-
tion of BAF at Ser 4 (Park et al., 2015). CDK5/p35 complex 
was identified as a regulator of VRK3 by phosphorylating 
VRK3 at Ser 108, which resulted in increase of its affinity to 
VHR (Song et al., 2016a). VRK3 also interacts with HSP70 
and promotes nuclear localization of glutamate-induced 
HSP70, which leads to activation of VHR activity (Song et al., 
2016b). Due to the limited numbers of identified binding 
partners of VRKs, their roles in various biological processes 
remain elusive. Thus, it is important to identify novel interact-
ing proteins of VRKs to clarify their roles. 
Though only limited numbers of proteins were identified 
as interacting proteins of VRK1 or VRK3, their crucial roles 
during cell division seem to be obvious. VRK1 depletion in-
duces the G1 arrest by downregulating cyclin D1 and p-Rb, 
and upregulating p21 and p27 in hepatocellular carcinoma 
(HCC), suggesting the crucial role of VRK1 in G1/S transition 
(Lee et al., 2015b). Regulation of cyclin D1 expression by 
VRK1 is mediated by phosphorylating the CREB transcription 
factor which upregulated the mRNA level of cyclin D1 (Kang 
et al., 2008; Lee et al., 2015b). VRK1 also coordinates sever-
al steps of mitosis. Phosphorylated VRK1 by polo-like kinase 
promotes Golgi fragmentation in G2/M phase (Lopez-
Sanchez et al., 2009). Chromatin condensation, one of the 
crucial steps in mitosis, is enhanced via phosphorylation of 
histone H3 on Ser 10 by VRK1 (Lopez-Sanchez et al., 2009). 
Interestingly, nuclear envelope assembly and disassembly 
during mitosis are regulated by both VRK1 and VRK3 
through the phosphorylation of BAF. During mitosis, VRK1 
phosphorylates BAF in Ser 4, Thr 2 and Thr 3, which results 
in nuclear envelope disassembly required for the progression 
of mitosis (Gorjanacz et al., 2007; Nichols et al., 2006). Dur-
ing interphase, phosphorylation of BAF on Ser 4 by VRK3 
promoted the disassembly of BAF, LEM proteins, and chro-
matin, which might result in the DNA replication (Park et al., 
2015). Interaction of BAF with both VRK1 and VRK3 may 
imply the functional links during the specific biological pro-
cesses. At the same time, distinct phosphorylation sites of 
BAF by VRK1 or VRK3, and involvement of phosphorylated 
BAF by VRK1 or VRK3 in the different steps during the cell 
cycle might suggest their distinct roles during the cell cycle. 
Comparing the interactomes of the same family proteins 
could provide new insights into their functional differences 
and redundancies. For instance, the phylogenetic relation-
ships and functional similarities among 11 histone deacety-
lases (HDACs) were observed by building a global protein 
interaction network for HDACs (Joshi et al., 2013). We pre-
viously compared the interactomes of two sirtuin family pro-
teins, SIRT6 and SIRT7, and revealed their functional links to 
aging based on shared interacting proteins (Lee et al., 2014). 
Thus, comparing the interactomes of VRK1 and VRK3 
should help to systematically identify global interaction net-
works and differences in interacting proteins and to reveal 
their common or distinct roles in specific biological processes 
such as cell cycle. 
In this study, we identified and compared VRK1- and 
VRK3-interacting candidate proteins by affinity purification 
and mass spectrometry under the same experimental condi-
tions. We identified 153 interacting candidate proteins for 
VRK1 and 92 interacting candidate proteins for VRK3, in-
cluding BAF, in agreement with previous findings. VRK1 and 
VRK3 shared 40 common interacting candidate proteins, 
indicating functional links between VRK1 and VRK3. The 
functional networks of the VRK1 and VRK3 interactomes 
were closely associated with the cell cycle, DNA repair, 
chromatin assembly, and RNA processing. The associations 
of nine interacting proteins with VRK1/VRK3 were further 
confirmed by co-immunoprecipitation and immunofluores-
cent staining. Phosphorylation levels of XRCC5 in serine resi-
dues were upregulated by VRK1/VRK3 overexpression. The 
phosphorylation of CCNB on threonine residues was specifi-
cally regulated by VRK3. We also found that VRK1 and VRK3 
have distinct roles on cell cycle progression in liver cancer. 
VRK3 silencing induced S phase and G2/M phase arrest, 
whereas VRK1 silencing induced G1 arrest in the liver cancer, 
which could be explained by their distinct interatomic pro-
teins involved in cell cycle progression. Our approaches and 
findings should be a valuable resource for investigating 
VRK1/VRK3 functions in the cell cycle, DNA repair, RNA pro-
cessing, and chromatin assembly. 
 
MATERIALS AND METHODS 
 
Co-immunoprecipitation 
Cells were harvested 24 h after transfection in cold PBS and 
centrifuged at 800 g. Cells were lysed with a lysis buffer con-
taining 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 
0.2% Triton X-100 and the inhibitor cocktail of proteases 
and phosphateases (Complete ULTRA Tablet and PhosSTOP, 
Roche). VRK1/VRK3 or p53, and their interacting proteins 
were pulled down with anti-flag M2 affinity gel (Sigma), 
eluted by boiling with Laemmli 2× Sample Buffer (Sigma) at 
100℃ for 5 min, and then subjected to Coomassie blue 
staining, Western blotting or in-solution digestion. 
 
In-solution digestion 
Proteins were digested with trypsin, as described in a previ-
ous study, with some modifications (Choi et al., 2011). Brief-
ly, eluted proteins were lyophilized and resolved in a diges-
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tion solution of 6 M urea and 40 mM ammonium bicar-
bonate in high-performance liquid chromatography (HPLC)-
grade water. Protein reduction was performed with 5 mM 
Tris (2-arboxyethyl) phosphine hydrochloride for 1 h, fol-
lowed by alkylation with 25 mM iodoacetamide in the dark 
for 30 min at room temperature. The sample was in-solution 
digested with 5 ng/mL sequencing-grade modified trypsin 
(Promega) for 16 h at 37℃. 
 
Nano-LC-MS/MS 
Peptides were analyzed using mass spectrometry, as de-
scribed previously, with some modifications (Choi et al., 
2011). Tryptic peptides from in-gel digestion were separated 
using a homemade microcapillary column (75 m x 12 cm) 
packed with C18 resin (Michrom Bioresources). Samples 
were eluted using a linear gradient of a mixture of solvents A 
(0.1% formic acid in 2% Acetonitrile) and B (0.1% formic 
acid in 98% Acetonitrile), where the percentage of the latter 
mobile phase increased over 120 min at a flow rate of 0.26 
l/min: 2-50% over 94 min, 50-90% over 6 min, 90% over 
6 min, 90-2% over 6 min, and 2% over 8 min. Eluted pep-
tides were analyzed with an LTQ Velos Orbitrap mass spec-
trometer (Thermo Finnigan) equipped with nano-ESI. MS 
precursor ion scans were acquired within a m/z range be-
tween 150 and 2000. The five most abundant ions detected 
in the precursor MS scan were dynamically selected for 
MS/MS analyses. Collision-induced dissociations of the se-
lected precursor ions were performed in an ion trap (LTQ) 
with 35% normalized collision energy. We employed dy-
namic exclusion to increase the size of proteome to be de-
tected as follows: repeat count for dynamic exclusion = 1, 
repeat duration = 30 s, dynamic exclusion duration = 180 s, 
and list size of dynamic exclusion = 50. 
 
Identification and quantification of proteins 
Peak lists of MS data were generated, and identifica-
tion/quantification of peptides and proteins from three 
technical replicates of LC-MS/MS data were performed using 
the MaxQuant quantification tool with Andromeda search 
engine (version 1.3.0.5). The top 10 peaks per 100 Da were 
used for analysis. Enzyme specificity for trypsin was used. 
The minimal peptide length was six amino acids, and two 
mis-cleavages were allowed. Variable modification options 
were employed for oxidation of methionine (15.995 Da) and 
carbamidomethylation of cysteine (57.021 Da). Tolerance 
was set to 10 ppm for precursor ions and 0.8 Da for frag-
ment ions. Swiss-Prot database (Homo sapiens reference 
proteome set, release 2013_01, 20,226 entries) with added 
contaminants and reverse sequences was used. For peptide 
and protein identification, 1% false discovery rate was de-
termined by accumulating 1% of reverse database hits. 
Common peptides shared by two proteins were combined 
and reported as one protein group. The first majority protein 
ID was selected as the representative protein of each group, 
and used as protein ID for further analysis. For comparison of 
samples, we used label-free quantification with a minimum 
of two ratio counts to determine the normalized protein 
label-free quantification (LFQ) intensity (Luber et al., 2010). 
Mass spectrometry proteomics data have been deposited in 
the Proteome Xchange Consortium (http://proteomecentral. 
roteomexchange.org) via the PRIDE partner repository (Vizcaino 
et al., 2013) with the dataset identifier, PXD004103. 
 
Definition of VRK1/3-interacting proteins 
For analysis of comparative proteomics, proteins with more 
than two unique peptides and lower than 0.01 posterior 
error probability were selected. We additionally removed all 
the reverse sequences and contaminant proteins. Using LFQ 
intensity, which represents the quantity of each identified 
proteins; fold change was calculated with the equation de-
scribed in a previous report (Yoon et al., 2011). 
 
fold change = LFQ samle – LFQ control Max (LFQ sample, LFQ control)
 
LFQ sample: Label-free quantitative intensity of each identi-
fied protein in the VRK1/VRK3-flag co-IP sam-
ples 
LFQ control: Label-free quantitative intensity of each identi-
fied protein in the flag co-IP samples. VRK1/ 
VRK3-interacting candidate proteins were iden-
tified as those enriched in the VRK1/VRK3-
positive sets, respectively, displaying more than 
0.5-fold change, which means at least 50% of 
proteins identified more in the VRK1/VRK3-
positive experimental set compared to VRK1/ 
VRK3-negative control set. 
 
Subcellular localization and phosphorylation of proteins 
To analyze subcellular localization and phosphorylation of 
the proteome, we extracted the related information from 
UniProt. P-values for localization and phosphorylation of 
proteins compared with the whole proteome were assessed 
by Fisher’s test. P-values for phosphorylated residues per 
protein were obtained by use of the Student’s t-test. 
 
Systematic analysis 
DAVID 6.7 was employed for Gene Ontology analysis. Bio-
logical Process terms of Gene Ontology were used, and P-
values were calculated with modified Fisher’s exact test. The 
protein-protein interaction database from the NCBI Entrez 
Gene, updated on Feb 17 in 2013, was applied to build the 
hypothetical network, which was visualized with Cytoscape 
2.8.3. 
 
Cell culture, reagents and plasmids 
The SK-Hep1, Hep3B, Huh-7, HepG2 and SNU449 cell lines 
were obtained from the Korean Cell Line Bank (Korea). SH-
J1 cells were provided by Dr. Dae-Ghon Kim (Medical School, 
Chonbuk National University) (Kim et al., 2002). HEK293FT 
and THLE-2 cells were purchased from Invitrogen and Amer-
ican Type Culture Collection (USA), respectively. HEK293FT 
and liver cancer cells were cultured at 37℃ under 5% CO2 in 
DMEM supplemented with 10% FBS, 100 units/ml of peni-
cillin and 100 g/ml streptomycin. THLE-2 cells originated 
from human primary normal liver cells were plated on cul-
ture plates pre-coated with a solution containing 0.01 
mg/ml fibronectin, 0.03 mg/ml bovine collagen type I and 
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0.01 mg/ml bovine serum albumin dissolved in Bronchial 
Epithelium Basal Medium (BEBM, Lonza). THLE-2 cells were 
cultured at 37℃ under 5% CO2 in BEBM supplemented 
with Bronchial Epithelium Cell Growth Medium (BEGM) 
SingleQuots (Lonza). Lipofectamine 2000 (Invitrogen) was 
used to transfect expression vectors into cells. The same 
control, VRK1, VRK3 and p53 expression vectors were used 
as described previously (Kang and Kim, 2006; Kang et al., 
2008; Lee et al., 2015b). 
 
Small interfering RNAs (SiRNAs) and electrophoresis 
For VRK3 gene silencing, cells were transfected with duplex 
siRNA specifically targeting VRK3 or negative control. siRNAs 
were synthesized from Bioneer (Korea) and sequences are 
following; negative control, 5’-CCU ACG CCA CCA AUU 
UCG U(dTdT)-3’; siVRK3, 5’-GGA CAA AUU GCC UUC CCA 
A(dTdT)-3’. Transient transfections for siRNAs were per-
formed by electroporation using a Microporator MP-100 
(Digital Bio) or Neon-Transfection System (Invitrogen). 
 
SDS-PAGE and Western blotting 
Co-immunoprecipitation samples were subjected to SDS-
PAGE on acrylamide gel. For Commassie blue staining, the 
acrylamide gel was stained with Brilliant Blue R250 Protein 
solution (Elpis, Korea) for 1 h with gentle agitation and then 
washed three times with destaining solution containing 
20% methanol and 10% acetic acid for 1 h. For Western 
blotting, SDS-PAGE gel was transferred onto PVDF mem-
branes (Millipore). After blocking with 5% skimmed milk in 
TBS-T buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% 
Tween20) for 1 h, membranes were incubated with the 
primary antibodies at 4℃ with shaking overnight. After in-
cubated with the secondary antibody for 2 h, immunocom-
plexes were detected by use of the femto, Pico or ECL rea-
gent (Thermo). Antibodies for Western blotting are from the 
companies as follows: mouse/rabbit anti-flag antibody (Sig-
ma), mouse anti-VRK1 (Santa Cruz), rabbit anti-VRK3 (Sig-
ma), mouse ant-ALY antibody (Santa Cruz), rabbit anti-
hsp70 (Origene), rabbit anti-XRCC5 (Santa Cruz), rabbit 
anti-B23 antibody (Santa Cruz), rabbit anti-C23 antibody 
(Santa Cruz), rabbit anti-PARP1 antibody (Cell signaling), 
rabbit anti-cyclin B1 (Santa Cruz), rabbit anti-p53 (Cell sig-
naling) and rabbit anti-BAF [previously used (Kim et al., 
2015)]. 
 
Immunocytochemical staining 
HEK293FT cells were seeded on cover slips coated with poly-
D-lysine, fixed with 4% paraformaldehyde in PBS, permea-
bilized with 0.1% Triton X-100 in PBS, and subsequently 
blocked with 1% BSA in PBS for 1 h. To verify the cellular 
localization of VRK1 and VRK3 expressed ectopically, the 
cells were incubated with mouse/rabbit anti-GFP antibody 
(Sigma) in the 4℃ overnight. The cells were washed with 
PBS three times and incubated with anti-mouse/rabbit Alexa 
Fluor 488 (Invitrogen) and anti-rabbit/mouse/goat Alexa 
Fluor 594 (Invitrogen) for 1 h at room temperature in the 
dark. Cells were subsequently washed with PBS, incubated 
with Hoechst 33342 (Invitrogen) for 10 min at room tem-
perature, and mounted with Mounting medium (Dako). 
Detection of phosphorylated proteins 
To detect phosphorylated interacting proteins, we performed 
immunoprecipitation experiments using mouse anti-phospho 
(p)-serine (Sigma) or mouse anti-phospho (p)-threonine anti-
bodies (Santa Cruz), as previously described (Lee et al., 2015a). 
Briefly, transfected cells were suspended in 180 l lysis buffer 
and 20 l 10% SDS (final concentration of SDS, 1%). The 
samples were boiled for 10 min to denature proteins. Then, 
1.8 ml of lysis buffer containing protease and phosphatase 
inhibitors was added to the samples (final concentration of 
SDS, 0.1%). The lysates were immunoprecipitated overnight 
4℃ with 2 l of anti-p-serine or anti-p-threonine antibody, 
and 30 l of protein G agarose beads were added and incu-
bated for an additional 2 h. The beads were washed three 
times with lysis buffer, and the precipitated proteins were 
eluted in Laemmli 2× sample buffer (Sigma) at 100℃ for 5 
min. Phosphorylated interacting candidates were detected 
by immunoblotting using rabbit cyclin B1 (Cell signaling) and 
rabbit anti-XRCC5 (Santa Cruz) antibodies. 
 
Gene expression data 
In an attempt to compare the mRNA levels of VRK1/VRK3 in 
non-tumor tissues and HCC, Gene expression data was ob-
tained from the National Center for Biotechnology Infor-
mation (NCBI) Gene Expression Omnibus (GEO) database 
(accession numbers are GSE57958 and GSE45436). 
 
Cell cycle analysis 
To analyze the progression of the cell cycle on asynchronous 
cell populations, 8  104 cells were seeded onto 6-well plates, 
transiently transfected with negative control or VRK3-specific 
siRNA and grown for 36 h. Cells were then collected by tryp-
sinization, fixed in the fixation solution containing 70% eth-
anol and 0.5% Tween-20, washed with PBS containing 1% 
BSA, resuspended in 200 l PBS containing 100 g/ml 
RNase (Sigma) and 50 g/ml propidium iodide (Sigma), in-
cubated in the dark for 40 min at room temperature, and 
analyzed using the Canto II flow cytometer (BD Biosciences). 
Acquired data were analyzed using ModFit LT software (Ver-
ity Software House). Four independent experiments were 
performed. 
 
RESULTS AND DISCUSSION  
 
Identification of VRK1- and VRK3-interacting proteins by 
LC-MS/MS 
To identify VRK1/VRK3-interacting proteins, we performed 
sequential experiments as shown in Fig. 1A. Initially, the flag-
conjugated VRK1/VRK3 expression vectors were transiently 
transfected into HEK293FT cells, which have been widely 
used to identify interacting proteins by co-immunoprecipitation 
coupled with mass spectrometry (Law et al., 2009; 2014; 
Miteva and Cristea, 2013; Tsai et al., 2012). Artificial tagging 
can mislocalize proteins within cells, therefore, we verified 
the localization of flag-tagged VRK1/VRK3 proteins by im-
munofluorescent staining. Ectopically expressed VRK1/VRK3 
proteins were clearly localized in the nucleus of most cells in 
agreement with previous findings (Fig. 1B) (Roopra et al., 
2004). Using anti-flag affinity gel, flag-tagged VRK1/VRK3 
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Fig.1. Experimental scheme and analysis of VRK1- and 
VRK3-interacting proteins. (A) Experimental proce-
dures for affinity purification coupled with LC-
MS/MS analysis. Flag-tagged VRK1 and VRK3 pro-
teins were expressed in HEK293FT cells and im-
munoprecipitated with anti-flag antibody immobi-
lized on affinity gels. Immuno-complexes were elut-
ed and digested for LC-MS/MS analysis. (B) Localiza-
tion of transiently expressed VRK1 and VRK3. 
HEK293FT cells transfected with VRK1-flag and 
VRK3-flag expressing vector were fixed after 24 h, 
followed by probing with flag antibody and mito-
traker. Arrows indicate the cytoplasmic localization 
of VRK1 and VRK3. Images magnified 400X. Scale 
bar indicates 10 m. (C) SDS-PAGE and Coomassie 
blue staining of immunocomplexes. The arrow on 
the second and third lanes indicates VRK1 and VRK3, 
respectively. (D) Comparison of interacting proteins 
with those reported previously for VRK1- and VRK3-
interacting proteins. (E) Venn diagram comparing 
VRK1- and VRK3-interactomes. 
A                           B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C                    D 
 
 
 
 
 
                      E 
 
 
 
 
 
 
 
 
 
 
proteins were isolated together with bound proteins. The 
enrichment of VRK1/VRK3 with interacting proteins by co-
immunoprecipitation was confirmed by SDS-PAGE analysis 
(Fig. 1C). VRK1/VRK3 and co-isolated proteins were en-
riched from the affinity gel (Fig. 1C). The same samples were 
also used for in-solution digestion using a spin filter (Manza 
et al., 2005; Wisniewski et al., 2009) and LC-MS/MS analysis 
of tryptic peptides with an LTQ Velos Orbitrap mass spec-
trometer, which was performed in triplicate. A database 
search using MaxQuant software followed by LFQ revealed 
VRK1/VRK3-interacting candidate proteins. We character-
ized 174 and 144 proteins (Supplementary Table 1) from a 
total of 996 and 574 unique peptides, respectively (Supple-
mentary Table 2), using the in-solution digested samples. We 
selected candidate proteins with unique peptides identified 
more than twice with a posterior error probability of lower 
than 0.01 for further analysis and eliminated all reverse se-
quences and contaminant proteins. We enriched 152 poten-
tial interacting candidates for VRK1 and 92 potential inter-
acting candidates for VRK3 (Fig. 1D; Supplementary Table 3). 
We identified three interacting proteins of VRK1 and two 
interacting proteins of VRK3 that had been identified previ-
ously (Fig. 1D). Overall, the interactomes we identified for 
VRK1/VRK3 contained many novel VRK1- and VRK3-
interacting candidate proteins. To confirm a functional link 
between VRK1 and VRK3, we compared their binding part-
ners. We identified 40 common potential interacting part-
ners (Fig. 1E), implying that VRK1 and VRK3 share common 
functions. 
 
Systematic analyses of VRK1/VRK3 interactomes 
We investigated the biological relevance of the VRK1/VRK3 
interactomes. First, we confirmed the subcellular localiza-
tions of VRK1/VRK3-interacting candidate proteins. Nuclear 
and cytoplasmic proteins were enriched, reflecting the nu-
clear and cytoplasmic localization of VRK1/VRK3 (Fig. 2A). 
Because VRK1 and VRK3 are kinases, we measured the per-
centages of phosphorylated proteins and found that the 
proportion of phosphorylated proteins were significantly 
higher in the VRK1 and VRK3 interactomes than in the 
whole proteome (whole proteome, 8.7%; VRK1 interac-
tome, 71.7%; VRK3 interactome, 77.2%; P > 0.05; Fig. 2B). 
 
Network analysis of VRK1/VRK3 interactomes 
Functional enrichment and subsequent interactome analyses 
reflected various functions of VRK1/VRK3, including chro-
matin assembly, RNA processing, cell cycle, and DNA repair. 
To confirm proteins corresponding to specific functions, we 
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Fig. 2. Systematic Analysis of VRK1 and VRK3 interactomes. (A)
Subcellular localizations of VRK1 and VRK3 interactomes. (B)
Percent of phosphorylated proteins in the whole proteome and
VRK1 and VRK3 interactomes. Fisher's test was used for statisti-
cal analysis. (*P < 0.001) (C) GO biological process network
delineating the relationship between VRK1- and VRK3-
interacting proteins. The intensity of node colors indicates fold
change of interacting proteins in co-IP samples. Red and blue
circles indicate the enrichment of indicated proteins in VRK1
and VRK3 co-IP samples, respectively. Each functional module
of the interacting partners outlined with color; cell cycle (red),
DNA repair (green), chromatin assembly (black) and RNA pro-
cessing (blue). Edges were drawn based on the public protein-
protein interaction database (gray). 
A                    B 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
established a network model utilizing the VRK1- and VRK3-
interacting candidate proteins involved in these four functions 
(chromatin assembly, RNA processing, cell cycle, and DNA 
repair; Fig. 2C). In the network analysis, 12 common poten-
tial interacting proteins, 29 VRK1-interacting candidate pro-
teins, and 11 VRK3-interacting candidate proteins were 
identified. Consistent with previous findings (Gorjanacz et al., 
2007; Park et al., 2015), BAF was identified in both VRK1 
and VRK3 interactomes (Fig. 2C). This interaction is crucial 
for VRK1 and VRK3 function in cell cycle progression. VRK1 
phosphorylates BAF at three sites, Ser4 and/or Thr2/Thr3, for 
the progression of mitosis (Nichols et al., 2006). VRK3 phos-
phorylates BAF at Ser4 for DNA replication during interphase 
(Park et al., 2015). We also identified 10 novel VRK1- or 
VRK3-interacting candidate proteins involved in the cell cycle, 
including cyclin B1 (CCNB1), centriolin (CTNRN), and spin-
dlin-1 (SPIN1) (Fig. 2C). Interestingly, SPIN1, a meiotic spin-
dle-binding protein, was suggested to be phosphorylated in 
a cell cycle-dependent manner and plays a role in cell cycle 
regulation (Oh et al., 1997). Although SPIN1 phosphoryla-
tion on Thr 95 was reported to be crucial for its proper func-
tions (Zhao et al., 2007), a kinase phosphorylating SPIN1 has 
not been identified yet. Because SPIN1 was identified as a 
VRK3-interacting candidate proteins, it may be phosphory-
lated by VRK3. CTNRN is a centrosome component that 
regulates cell cycle progression during interphase and mitosis 
(Hinchcliffe, 2003). Regulators for CTNRN have not been 
identified. Because CTNRN and SPIN1 are critical for cell cycle 
progression, VRK3-mediated regulation of SPIN1 or CTNRN 
functions in cell cycle should be investigated further. 
Our interactomes included 10 novel VRK1/VRK3-interacting 
candidate proteins involved in DNA repair, such as nucleo-
phosmin (NPM1), nucleolin (NCL), X-ray repair cross-
complementing protein 5 (XRCC5), heat shock 70 kDa pro-
tein 1A/1B (HSPA1A), and poly [ADP-ribose] polymerase 1 
(PARP1) (Fig. 2C). Phosphorylation of these proteins is im-
portant for their functions. For example, phosphorylation is 
crucial for maximal PARP1 activation after DNA damage 
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Fig. 3. Validation of interacting proteins with VRK1 and VRK3.
Co-immunoprecipitation of interacting proteins with VRK1 
(A) and VRK3 (B). Co-immunoprecipitation was performed 
by mixing flag antibody-conjugated beads with cell lysates of
HEK293FT cells transfected transiently with pCMV_flag, 
pCMV_VRK1-flag and pCMV_VRK3-flag. Target proteins 
associated with cell cycle or DNA repair such as NCL, PARP1, 
HSP70, XRCC5, p53, NPM1, BAF and CCNB, and RNA pro-
cessing such as ALYREF were confirmed by Western blotting.
Fig. 4. Phosphorylation levels of XRCC5 and CCNB by expres-
sion of VRK1 or VRK3. Phosphorylation levels of XRCC5 (A) 
and CCNB (B) upon the overexpression of VRK1 or VRK3. 
Expression vectors for flag, VRK1-flag and VRK3-flag, were 
transfected into HEK293FT cells. After 24 h, cells were lysed, 
immunoprecipitated with anti-phosphoserin or anti-phospho-
threonine antibodies immobilized on agarose beads, and 
then subjected to Western blotting. 
(Kauppinen et al., 2006). Phosphorylated NPM1 is recruited 
to the foci of DNA damage and promotes Ring Finger Pro-
tein 8-dependent DNA repair (Koike et al., 2010). Because 
those proteins have been identified as VRK1/ VRK3-
interacting candidate proteins, VRK1/ VRK3 might regulate 
the phosphorylation of these proteins. 
Proteins involved in RNA processing such as heterogene-
ous nuclear ribonucleoproteins (hnRNPs) and THO complex 
subunit 4 (ALYREF) were also identified in our interactomes 
(Fig. 2C). ALYREF and HnRNPs are RNA-binding proteins and 
are involved in RNA processing (Han et al., 2010). We previ-
ously reported the interaction of HnRNP A1 with VRK1 (Choi 
et al., 2012), but the association of VRK1 or VRK3 with RNA 
processing needs to be investigated. Many histones involved 
in chromatin assembly were also identified as VRK1- and 
VRK3-interacting candidate proteins (Fig. 2C). Nuclear VRK1 
and VRK3 might regulate chromatin structure and gene 
expression by phosphorylating histone proteins. Thus, the 
interactomes we have identified for VRK1 and VRK3 imply 
crucial roles in the cell cycle, DNA repair, RNA processing, 
and chromatin assembly. 
 
Confirmation of the specific interactions between 
VRK1/VRK3 and their binding proteins 
We demonstrated that VRK1 and VRK3 interact with pro-
teins involved in DNA repair, the cell cycle, and RNA pro-
cessing by co-immunoprecipitation and Western blotting. 
These interaction partners included NCL, PARP1, HSP70, 
XRCC5, TP53, NPM1, BAF, CCNB1, and ALYREF. We co-
immunoprecipitated these proteins with VRK1/VRK3 in 
VRK1/3-expressing HEK293FT cell lysates, except for TP53 
and CCNB1, which were only detected in VRK3-enriched 
samples consistent with our mass spectrometry data (Figs. 3A 
and 3B). Interestingly, TP53 was not co-immunoprecipitated 
with VRK1 in detectable quantities under our experimental 
conditions. TP53 was previously shown to be a VRK1 sub-
strate (Lopez-Borges and Lazo, 2000; Lopez-Sanchez et al., 
2014; Vega et al., 2004); therefore, we further tested the 
interaction of VRK1 and VRK3 with p53 by reciprocal co-
immunoprecipitation. Consistent with our mass spectrome-
try data, only VRK3, not VRK1, was co-immunoprecipitated 
with p53 (Supplementary Fig. 1A). This discrepancy with 
previous reports might be explained by different conditions 
of immunoprecipitation. Because VRK3 strongly binds with 
p53, p53 might be a direct substrate of VRK3. Specific bind-
ing of VRK3 to CCNB1 implies that VRK1 and VRK3 are 
functionally linked by shared interaction proteins and exe-
cute distinct functions by regulating specific target proteins. 
 
Phosphorylation levels of XRCC5 and cyclin B1 by 
VRK1/VRK3 
As VRK1 and VRK3 are kinases, we investigated the phos-
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Fig. 5. Characterization of interaction of CCNB with
VRK3 in the liver cancer. (A) The levels of VRK3 in
THLE-2 cells immortalized normal cell line, and six
liver cancer cell lines were analyzed by Western blot-
ting. (B) Analysis of VRK3 expression in HCC and
non-tumor tissues using microarray dataset obtained
from the GEO database. Student's t-test was used for
statistical analysis. (*P < 0.05) (C) Expression levels of
VRK3 in SK-Hep1 and SH-J1. VRK3 levels were re-
duced in the SK-Hep1 and SH-J1 cells 36 h after
transfection with VRK3 siRNA as judged by Western
blotting. (D) Cell cycle analysis of VRK3-depleted SK-
Hep1 and SH-J1. SK-Hep1 and SH-J1 were transfect-
ed with control and VRK3 siRNAs and grown for 36
h, after which they were stained with propidium
iodide (PI) and subjected to FACS analysis. The num-
ber of SK-Hep1 and SH-J1 cells at G1, S and G2/M
phase was quantified. The Modifit program was used
for data analysis. Four independent experiments were
performed and representative FACS data are shown
(left). The percentages of cells at G1, S and G2/M
phase are indicated in the histogram (right). (n.s., not
significant; *P < 0.05; **P < 0.01) (E-G) Co-immuno-
precipitation of CCNB with VRK1 in SK-Hep1 (E), SH-
J1 (F) and Hep3B (G). Co-immunoprecipitation was
performed by mixing flag antibody-conjugated beads
with cell lysates of three liver cancer cell lines trans-
fected transiently with pCMV_flag or pCMV_VRK3-
flag, and then subjected to Western blotting. 
phorylation of interaction partners. We first checked the 
phosphorylation levels of XRCC5 which could bind to both 
VRK1 and VRK3 (Fig. 4A). We overexpressed VRK1/VRK3 in 
HEK293FT cells using expression vectors. Immunoprecipita-
tion using anti-phosphoserine or anti-phosphothreonine 
antibodies enriched phosphorylated proteins, and changes 
in the phosphorylation levels of interacting proteins were 
confirmed by Western blotting of interacting proteins. Phos-
phorylated serine residues on XRCC5 were increased by VRK1 
or VRK3 overexpression, suggesting that both VRK1 and 
VRK3 might regulate phosphorylation levels of XRCC5. 
Though phosphorylation sites of XRCC5 have been identified 
(Douglas et al., 2005), the role of phosphorylation on XRCC5 
is unclear. Thus, roles of VRK1/VRK3-mediated phosphoryla-
tion on XRCC5 are warrant for further investigation. 
We next confirmed the phosphorylation levels of cyclin B1 
which specifically binds to VRK3. The phosphorylation levels 
of cyclin B1 at threonine residues were increased after VRK3 
overexpression (Fig. 4B), indicating that cyclin B1 is phos-
phorylated by VRK3. VRK1 overexpression did not affect the 
phosphorylation levels of cyclin B1 (Fig. 4B), indicating spe-
cific regulation of cyclinB1 by VRK3. Phosphorylation of cy-
clin B1 at serine residues is important for its nuclear translo-
cation (Li et al., 1997). Polo-like kinase (Plk)-1 is a cyclin B1 
kinase that phosphorylates Ser147 and/or Ser133 (Toyoshima-
Morimoto et al., 2001). Interestingly, we found that VRK3 
may also be a kinase for cyclin B1. Unlike Plk1, VRK3 phos-
phorylated cyclin B1 at threonine residues. Elucidation of the 
specific cyclin B1 threonine residues that are phosphorylated 
by VRK3 and the physiological relevance of this phosphoryla-
tion should contribute to our understanding of the molecu-
lar role of VRK3 during cell cycle progression. 
 
Distinct effect of VRK3 on the cell cycle progression of 
liver cancer 
Since VRK1 and VRK3 specifically bind to distinct interacting 
proteins involved in cell cycle such as EVI5, HMGA2, MAD1L1 
for VRK1 and CCNB, SPIN1, CNTRL etc. for VRK3 (Fig. 2C), 
respectively, we tested whether VRK3 could differently affect 
the cell cycle progression compared with VRK1. We previ-
ously reported that VRK1 could promote liver cancer pro-
gression by promoting G1/S transition (Lee et al., 2015b). 
Thus we chose the liver cancer as an experimental model 
system to compare the effects of VRK3 and VRK1 on the cell 
cycle progression of liver cancer. We first checked the ex-
pression levels of VRK3 in the liver cancer. VRK3 levels were 
higher in six liver cancer cell lines than THLE-2 cell line, an 
immortalized cell line (Fig. 5A). Consistently, publicly availa-
ble datasets showed high expressions of VRK3 in hepatocel-
lular carcinoma (HCC) tissues compared with non-tumor 
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tissues (Fig. 5B). We also confirmed high expression of VRK1 
in HCC tissues and liver cancer cell lines using the same da-
tasets as well as in the same liver cancer cell lines (Supple-
mentary Fig. 2A), which is consistent with our previous re-
port showing oncogenic potential of VRK1 in liver cancer 
(Lee et al., 2015b). 
To understand the effect of VRK3 on cell cycle of liver can-
cer cells, we performed FACS analyses after transfection with 
control or VRK3 siRNA. Western blotting showed that VRK3 
was efficiently silenced by transfection of VRK3 siRNA in SK-
Hep1 and SH-J1 cells (Fig. 5C). Interestingly, the number of S 
phase gated cells was significantly higher in VRK3 depleted-
SK-Hep1 and SH-J1 cells than control cells, whereas the 
number of G1 phase gated cells was lower in VRK3 depleted 
cells than control cells (Fig. 5D). The number of G2/M phase 
gated cells were not changed by VRK3 silencing (Fig. 5D). 
These data indicate distinct effects of VRK3 in cell cycle pro-
gression of liver cancer cell when compared with VRK1 
whose depletion induced the G1 arrest (Lee et al., 2015b). 
We think that different effects of VRK1 and VRK3 on cell 
cycle progression could be mediated by different interact-
ing proteins. Thus, we re-validated the interaction of CCNB1 
with VRK3 in three liver cancer cell lines, because CCNB1 
was identified to specifically bind to VRK3 in HEK293FT 
cells. In addition, CCNB1 has been shown to regulate not 
only mitosis entry (Gavet and Pines, 2010) and exit 
(Potapova et al., 2006), but also S phase progression (Moore 
et al., 2003). Consistent with our result, CCNB1 was clearly 
co-immunoprecipitated with VRK3 in three liver cancer cell 
lines (Figs. 5E-5G). 
Figure 6 shows the schematic model of the distinct roles of 
VRK1 and VRK3 in the cell cycle progression of liver cancer. 
Our group previously reported that VRK1 regulates the G1/S 
transition via phosphorylating the CREB protein which up-
regulates CCND1, thus VRK1 depletion induces the G1 ar-
rest (Lee et al., 2015b). Interestingly, in this study, we found 
that VRK3 could also affect cell cycle progression but it 
seemed to regulate different stage of cell cycle progression 
in liver cancer. A higher number of S phase gated cells in 
VRK3 silenced cells might indicate that VRK3 depletion in-
duced S phase arrest. If VRK3-depleted cells have defects 
only in S phase, the number of both G1 and G2/M phase 
gated cells should be decreased in VRK3 depleted cells than 
control cells in the cell cycle. However, the number of G2/M 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Schematic diagram of the distinct roles of VRK1 and VRK3 
during the cell cycle progression in liver cancer. 
phase gated cells was not changed by VRK3 depletion, even 
though G1 phase gated cells were decreased in VRK3 de-
pleted cells (Fig. 5D). Thus, VRK3-depleted cells might also 
have defects in G2 or M phase entry and exit. These phe-
nomena could be related with the roles of VRK3-interacting 
candidate proteins. First, CCNB1 is crucial for the progression 
of the cells entry (Gavet and Pines, 2010) and exit (Potapova 
et al., 2006) of M phase. CCNB1 also has S-phase promoting 
abilities (Moore et al., 2003). Thus, VRK3 defects might af-
fect the activity of CCNB1 via regulation of phosphorylation 
levels, which results in the defects on M phase entry and exit 
and/or S phase progression. Second, CTNRL is necessary for 
a late stage of cytokinesis, the cytoplasmic division of a cell at 
the end of mitosis (Hinchcliffe, 2003). CTNRL is involved in 
the spindle position checkpoint. CTNRL deficiency induces 
improper spindle position, which results in M phase arrest 
(Pereira and Schiebel, 2001). Thus, the effect of VRK3 on 
G2/M phase might be mediated by CTNRL functions. Third, 
overexpression of SPIN1 was known to have a different cell 
cycle distribution in S and G2/M phases (Gao et al., 2005; 
Zhao et al., 2007). Phosphorylation levels of SPIN1 are also 
altered in the cell cycle-dependent fashion (Oh et al., 1997). 
Thus, the effect of VRK3 on G2/M or S phase might be me-
diated by functions of SPIN1. Though we explained the de-
fects of cell cycle progression by VRK3 silencing via known 
functions of interacting candidates, our model remains to be 
investigated to elucidate the molecular role of VRK3 during 
the cell cycle progression. 
 
CONCLUSION 
 
We systematically identified the proteins that interact with 
VRK1/VRK3 by affinity purification coupled with LC-MS/MS 
analysis. Using this approach, we identified novel VRK1/VRK3-
interacting candidate proteins while confirming those which 
were already known. We validated interactions of the novel 
candidate proteins with VRK1/VRK3 by co-immunoprecipitation. 
VRK1/VRK3 regulated the phosphorylation of XRCC5. The 
phosphorylation of CCNB was specifically regulated by VRK3. 
We also suggested distinct effects of VRK1 and VRK3 on cell 
cycle progression in liver cancer, which could be affected 
differentially by distinctly different interacting candidate pro-
teins. VRK3 seemed to affect S phase progression and G2 or 
M phase entry and exit, whereas VRK1 affects G1/S transi-
tion in the liver cancer. Overall, this study provides a resource 
for studying VRK1 and VRK3 functions as well as evidences 
that VRK1/VRK3 are functionally important in cell cycle regu-
lation, mRNA processing, chromatin assembly, and DNA 
repair. 
 
Note: Supplementary information is available on the Mole-
cules and Cells website (www.molcells.org). 
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